Back to GetFilings.com



Table of Contents
 

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON DC 20549
 

 
FORM 10-Q
 
x
 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended June 30, 2002
 
OR
 
¨
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from __________ to __________.
 
Commission file number: 0-29975
 

 
ACLARA BioSciences, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
    
94-3222727
(State of incorporation)
    
(IRS Employer Identification Number)
 
1288 Pear Avenue
Mountain View, California 94043
(Address of principal executive offices and zip code)
 
650-210-1200
(Registrant’s telephone number, including area code)
 
Indicate by check mark whether registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    YES  x    NO  ¨.
 
The number of shares outstanding of the registrant’s common stock as of July 31, 2002 was 36,154,955.
 


Table of Contents
 
ACLARA BIOSCIENCES, INC.
 
TABLE OF CONTENTS
 
         
PAGE

Part I:
  
Financial Information
    
    Item 1.
  
Financial Statements (Unaudited)
    
       
3
       
4
       
5
       
6
    Item 2.
     
7
    Item 3.
     
15
Part II:
  
Other Information
    
    Item 1.
     
15
    Item 2.
     
16
    Item 3.
     
16
    Item 4.
     
16
    Item 5.
     
17
    Item 6.
     
17
  
20

2


Table of Contents
 
PART I—FINANCIAL INFORMATION
 
ITEM 1.    Financial Statements
 
ACLARA BIOSCIENCES, INC.
(A Company in the Development Stage)
 
CONDENSED BALANCE SHEETS
(In Thousands, Except Share and Per Share Amounts)
(Unaudited)
 
    
June 30, 2002

    
December 31, 2001

 
ASSETS
                 
Current assets:
                 
Cash and cash equivalents
  
$
45,780
 
  
$
30,970
 
Restricted cash
  
 
34,125
 
  
 
34,125
 
Short-term marketable investments
  
 
30,917
 
  
 
45,883
 
Accounts receivable
  
 
152
 
  
 
1,540
 
Prepaid expenses and other current assets
  
 
629
 
  
 
546
 
Inventories
  
 
42
 
  
 
14
 
    


  


Total current assets
  
 
111,645
 
  
 
113,078
 
Long-term marketable investments
  
 
48,316
 
  
 
60,598
 
Restricted cash
  
 
 
  
 
500
 
Property and equipment, net
  
 
9,356
 
  
 
8,887
 
Other assets, net
  
 
100
 
  
 
119
 
    


  


Total assets
  
$
169,417
 
  
$
183,182
 
    


  


LIABILITIES & STOCKHOLDERS’ EQUITY
                 
Current liabilities:
                 
Accounts payable
  
$
941
 
  
$
974
 
Accrued payroll and related expenses
  
 
1,057
 
  
 
1,077
 
Accrued expenses and other current liabilities
  
 
2,908
 
  
 
1,987
 
Deferred revenue
  
 
519
 
  
 
596
 
Litigation settlements accrual
  
 
30,541
 
  
 
27,197
 
Current portion of loans payable
  
 
57
 
  
 
55
 
    


  


Total current liabilities
  
 
36,023
 
  
 
31,886
 
Loans payable, net of current portion
  
 
478
 
  
 
507
 
Deferred rent
  
 
378
 
  
 
322
 
    


  


Total liabilities
  
 
36,879
 
  
 
32,715
 
Contingencies (Note 3)
                 
Stockholders’ equity:
                 
Common stock, $0.001 par value:
                 
Authorized 150,000,000 shares; Issued and outstanding: 36,148,437 shares at June 30, 2002 and 35,871,066 shares at December 31, 2001
  
 
36
 
  
 
36
 
Additional paid-in capital
  
 
259,235
 
  
 
259,327
 
Deferred stock-based compensation
  
 
(1,695
)
  
 
(2,785
)
Stockholder notes receivable for common stock
  
 
(579
)
  
 
(571
)
Accumulated other comprehensive income
  
 
308
 
  
 
281
 
Deficit accumulated during development stage
  
 
(124,767
)
  
 
(105,821
)
    


  


Total stockholders’ equity
  
 
132,538
 
  
 
150,467
 
    


  


Total liabilities and stockholders’ equity
  
$
169,417
 
  
$
183,182
 
    


  


 
The accompanying notes are an integral part of these condensed financial statements.

3


Table of Contents
 
ACLARA BIOSCIENCES, INC.
(A Company in the Development Stage)
 
CONDENSED STATEMENTS OF OPERATIONS
(In Thousands, Except Per Share Data)
(Unaudited)
 
    
Three Months Ended
June 30,

    
Six Months Ended
June 30,

    
Cumulative
Period from
May 5, 1995
(Inception) to
June 30,
2002

 
    
2002

    
2001

    
2002

    
2001

    
Revenues
  
$
673
 
  
$
849
 
  
$
1,263
 
  
$
1,783
 
  
$
16,631
 
    


  


  


  


  


Costs and operating expenses:
                                            
Research and development
  
 
6,668
 
  
 
5,921
 
  
 
13,060
 
  
 
11,676
 
  
 
76,305
 
Selling, general and administrative
  
 
3,078
 
  
 
2,537
 
  
 
5,911
 
  
 
5,416
 
  
 
40,121
 
Litigation settlement
  
 
1,810
 
  
 
(2,389
)
  
 
3,344
 
  
 
2,388
 
  
 
43,391
 
    


  


  


  


  


Total costs and operating expenses
  
 
11,556
 
  
 
6,069
 
  
 
22,315
 
  
 
19,480
 
  
 
159,817
 
    


  


  


  


  


Loss from operations
  
 
(10,883
)
  
 
(5,220
)
  
 
(21,052
)
  
 
(17,697
)
  
 
(143,186
)
Interest income
  
 
1,037
 
  
 
2,014
 
  
 
2,130
 
  
 
4,689
 
  
 
21,230
 
Interest expense
  
 
(12
)
  
 
(13
)
  
 
(24
)
  
 
(26
)
  
 
(1,225
)
    


  


  


  


  


Net loss before extraordinary loss
  
 
(9,858
)
  
 
(3,219
)
  
 
(18,946
)
  
 
(13,034
)
  
 
(123,181
)
Extraordinary loss on early retirement of debt
  
 
—  
 
  
 
—  
 
  
 
—  
 
  
 
—  
 
  
 
(1,103
)
    


  


  


  


  


Net loss
  
$
(9,858
)
  
$
(3,219
)
  
$
(18,946
)
  
$
(13,034
)
  
$
(124,284
)
    


  


  


  


  


Dividends related to beneficial conversion feature of preferred stock
  
 
—  
 
  
 
—  
 
  
 
—  
 
  
 
—  
 
  
 
(5,000
)
Accretion to redemption value and accrued dividends on mandatorily redeemable convertible preferred stock
  
 
—  
 
  
 
—  
 
  
 
—  
 
  
 
—  
 
  
 
(6,292
)
    


  


  


  


  


Net loss attributable to common stockholders
  
$
(9,858
)
  
$
(3,219
)
  
$
(18,946
)
  
$
(13,034
)
  
$
(135,576
)
    


  


  


  


  


Net loss per common share, basic and diluted
  
$
(0.27
)
  
$
(0.09
)
  
$
(0.53
)
  
$
(0.37
)
        
Shares used in net loss per common share calculation, basic and diluted
  
 
36,051
 
  
 
35,360
 
  
 
35,955
 
  
 
34,892
 
        
 
The accompanying notes are an integral part of these condensed financial statements.

4


Table of Contents
ACLARA BIOSCIENCES, INC.
(A Company in the Development Stage)
 
CONDENSED STATEMENTS OF CASH FLOWS
(In Thousands)
(Unaudited)
 
    
Six Months Ended
June 30,

    
Cumulative
Period from
May 5, 1995
(Inception) to
June 30, 2002

 
    
2002

    
2001

    
CASH FLOWS FROM OPERATING ACTIVITIES:
                          
Net loss
  
$
(18,946
)
  
$
(13,034
)
  
$
(124,284
)
Adjustments to reconcile net loss to net cash used in operating activities:
                          
Depreciation and amortization
  
 
1,004
 
  
 
742
 
  
 
4,884
 
Amortization of discount on marketable investments
  
 
(276
)
  
 
(287
)
  
 
(3,113
)
Amortization of note and long-term debt discount
  
 
—  
 
  
 
—  
 
  
 
597
 
Amortization of deferred stock based compensation
  
 
705
 
  
 
1,353
 
  
 
11,926
 
Amortization of other assets
  
 
—  
 
  
 
25
 
  
 
81